SCHEMBL870673

SCHEMBL870673

COC(=O)c1ccc(C2=NOC(c3cc(F)c(F)c(C(F)(F)F)c3)(C(F)(F)F)C2)c2ccccc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
PDK2 Q15119 6/20 0.33
CFTR P13569 3/20 0.32
MAPT P10636 1/20 0.32
ABL1 P00519 1/20 0.31
SRC P12931 1/20 0.31
F2 P00734 2/20 0.30
F10 P00742 2/20 0.30
PRSS1 P07477 2/20 0.30
LMNA P02545 2/20 0.30
NPC1 O15118 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C19 P33261 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
GAA P10253 1/20 0.30
SOS1 Q07889 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL876196 0.90 KCNN4 (0.36) CA1CA2PDK2CFTRMAPT
SCHEMBL10072328 0.90 PDK2 (0.35) CA1CA2PDK2MAPTF2
SCHEMBL872468 0.90 CA1 (0.32) CA1CA2
SCHEMBL871010 0.88 KDM4E (0.33) PDK2MAPTNPC1
SCHEMBL871063 0.87 PDK2 (0.40) PDK2CFTRMAPTABL1SRC
SCHEMBL871262 0.86 PDK2 (0.40) CA1CA2PDK2MAPTF2
SCHEMBL869874 0.86 CFTR (0.37) CA1CA2PDK2CFTRMAPT
SCHEMBL870666 0.85 CFTR (0.34) CA1CA2PDK2CFTRMAPT
SCHEMBL871009 0.85 ALOX5AP (0.35) PDK2
SCHEMBL883522 0.84 F2 (0.31) F2F10PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2619189-B1 ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS ZOETIS SERVICES LLC (US) 2020-04-15 EP disclosed
EP-2619189-B1 ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS ZOETIS SERVICES LLC (US) 2020-04-15 EP disclosed
US-8404649-B2 Isoxazoline oximes as antiparasitic agents AH USA 42 LLC (US) 2013-03-26 US disclosed
US-8404649-B2 Isoxazoline oximes as antiparasitic agents AH USA 42 LLC (US) 2013-03-26 US disclosed
US-20120077765-A1 ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS PFIZER INC. (US) 2012-03-29 US disclosed
WO-2012038851-A1 ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS PFIZER INC. (US) 2012-03-29 WO disclosed
US-20120077765-A1 ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS PFIZER INC. (US) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077765-A1 ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS CYP1A2, CYP3A7, CYP2E1 CA1 2008/4885CA2 1391/4885PDK2 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.